COLUMN: 67,798 dead, and America finally dares to breathe, but cannot celebrate

The number is falling, but the chair remains empty

Good news written in mourning

67,798. That is the most recent preliminary estimate of the number of overdose deaths in the United States during the 12-month period ending in March 2026. The CDC released it on August 12 based on data available as of August 4. The decline amounts to 12.3% year-over-year. Behind this improvement are thousands of families who did not receive the call they feared.

Let’s be blunt: this is good news. Refusing to acknowledge it for fear of appearing naive would be cruel to those who distribute naloxone, open doors to treatment, support people struggling with addiction, and start over after every relapse. A death averted is not a footnote. It is a life that continues to matter.

But 67,798 is not peace

The number remains immense. It represents approximately 186 deaths per day when spread out over a year—an arithmetic conversion that does not claim to capture every actual day. The national decline does not erase the regions where mortality is rising, the communities where it remains disproportionately high, or the new substances that complicate the response.

We have the right to breathe a sigh of relief at the decline. We do not have the right to turn that sigh into a victory while nearly sixty-eight thousand absences still linger across the country.

Progress is not the opposite of grief. It is what grief demands of us.

An update that’s already changing the narrative

From February to March, the numbers are shifting

On August 7, an analysis based on the previous monthly report projected 68,641 deaths for the 12-month period ending in February 2026—a 12.1% decrease. Five days later, the CDC’s new update extended the period through March and revised the estimate to 67,798, representing a 12.3% decrease. This is not a contradiction. It reflects the nature of a provisional system that continuously receives, corrects, and adjusts death certificates.

The CDC recommends using projected provisional numbers rather than relying solely on deaths already reported. These estimates attempt to account for reporting delays and ongoing investigations. The most recent data is often the least complete. Therefore, the numbers may rise, fall, or be revised as records come in.

Caution Does Not Negate the Trend

Saying “preliminary” does not mean “imaginary.” The national trend has been declining since 2023, and the decline in 2025 was significant enough to affect nearly every state. The CDC warns that a decline or plateau in recent numbers may reflect a real decline, incomplete data, or both. The right word is neither triumph nor illusion. It is improvement.

The numbers change as reports come in. Lives, however, do not become provisional: each has already crossed over to the irreversible side of the statistics.

Revisable data can carry definitive pain.

A three-year perspective, finally

2025 confirms the trend

For 2025 as a whole, the CDC estimated in May that there were 69,973 overdose deaths, compared to 81,313 in 2024—a decrease of nearly 14%. This marked the third consecutive year of decline. Deaths involving opioids were estimated at 44,564, compared to 55,296 the previous year. Cocaine and psychostimulants were also on the decline in national data.

The trend began after a peak that exceeded 112,000 deaths over a 12-month period during the summer of 2023, according to figures cited by NPR. Going from that peak to fewer than 70,000 is no minor fluctuation. Something has changed. Several things, probably. The country has learned, distributed, treated, and monitored. The illicit supply has also evolved.

Recognizing the result without taking credit

No single actor can honestly take sole credit for this decline. Federal efforts, states, community teams, families, people who use drugs, emergency services, and treatment programs all likely play a role in explaining it. The composition of fentanyl and patterns of use may also be factors. Mortality data do not break down the causes.

Three years of decline prove that a national tragedy can be reversed. They do not prove that a single program, a single party, or a single border holds the solution.

The decline is real. Its cause is collective and still only partially known.

Naloxone has changed the landscape

An antidote that has become a first-aid tool

Naloxone reverses an opioid overdose when administered in time. Reuters reports that its widespread availability has significantly contributed to the decline, according to experts. NPR quotes public health officials who describe how access to it has become much more widespread in communities and how it has gradually transitioned to first-aid status. This cultural shift matters just as much as the kit itself.

For a long time, the tool remained shrouded in the stigma surrounding addiction. Making it visible, available, and understandable has shifted the focus: we no longer ask whether a person “deserves” to be saved. We ask whether someone can act quickly enough. That split second never shows up in national statistics. Yet it is the secret power of naloxone.

It Can’t Turn Everything Around

Naloxone acts on opioids. It does not neutralize all sedatives or all combinations found in the illicit drug supply. Narcotics.com notes, in particular, that xylazine is not an opioid. New substances can complicate the intervention, and a person alone may die without anyone there to administer the antidote.

Naloxone is neither a license to use drugs nor a complete solution. It is something simpler and more sacred: time given back to a body that was losing it.

Saving a life first does not preclude treatment later. It makes that “later” possible.

Treatment makes less noise than enforcement

Methadone and buprenorphine: duration

Reversing an overdose prevents immediate death. Treatment for opioid use disorder addresses the recurring risk. Methadone and buprenorphine reduce the symptoms and cravings that fuel dangerous use. Experts cited by NPR rank expanded access to these medications among the structural changes that can save lives.

Repression produces vivid images: seizures, arrests, borders, press conferences. Treatment often involves a less spectacular routine: appointments, supervised doses, transportation, insurance coverage, adjustments, and returning to treatment after a hiatus. Yet it is precisely through this routine that the crisis is overcome. A continuum of care remains less photogenic than a chain of command. It may be more effective.

Access remains a matter of geography

In rural Arizona, studies cited by NPR found that it takes more than two hours by car to access opioid treatment in some communities. Two hours is not an abstraction when a person is working, doesn’t have a car, is living with symptoms, or is simply trying not to relapse. The nationwide availability of a medication does not guarantee its presence within human reach.

Treatment that’s a two-hour drive away exists only on paper. For someone without transportation, time off work, or financial leeway, it remains nothing more than a door drawn on a wall.

Medicine saves lives only when it’s accessible.

The illicit supply chain may have changed

Less Potent Fentanyl: A Serious Hypothesis

Researchers and analysts cited by NPR and Medical Daily suggest that the potency of street fentanyl may have decreased in certain markets. Changes in chemical precursors, manufacturing, and supply chains can alter lethality without eliminating demand. This hypothesis helps explain why the decline may have been rapid and widespread.

It should not be treated as a national certainty. The illicit market is fragmented. A powder sold in Arizona does not necessarily have the same composition as a product circulating in New York. Death certificates show who has died and which substances are often involved; they do not, on their own, reveal the full picture of street chemistry or the supply chain that produced it.

The danger can evolve faster than policy

New sedatives and mixtures are emerging. Medetomidine and xylazine are being monitored because they can complicate overdoses and emergency response. The CDC’s categories are not mutually exclusive: a death may involve multiple drugs and be counted in multiple classes. The crisis does not move in neat waves. It layers substances, risks, and delays.

While the decline is partly due to less potent fentanyl, it may be fragile in the most brutal way: a clandestine change in the formula could undo what public health has gained.

When the poison changes without warning, the victory must remain adaptable.

America Declines, the West Rises

Three States Defy the Average

The CDC’s 2025 report indicates that nearly all states have recorded a decline. Rhode Island, New York, North Carolina, Alabama, and Vermont saw decreases of at least 25%. But New Mexico, Arizona, and Colorado posted increases of at least 10%. A national average can therefore improve while certain regions see their situation worsen.

This contrast precludes political celebrations. It calls for a local investigation into factors such as drug potency, methamphetamine distribution, access to care, rural settings, housing, poverty, naloxone availability, prescribing practices, and the capacity of healthcare systems. A solution that works in a densely populated New York neighborhood does not automatically translate to hundreds of kilometers of desert.

Zip codes factor into the risk

NPR reports that Arizona and New Mexico have large Native American populations and that overdose mortality among Indigenous people there remains much higher than in the rest of the population. This observation does not allow us to attribute any increase to a single community. Rather, it compels us to examine the inequalities in access and the inadequate infrastructure hidden behind the map.

A national decline can become a moral lie if it is used to turn a blind eye to the places where risk is rising, where treatment is far away, and where deaths remain concentrated.

The country is doing better. That does not mean that every community in the heartland is doing better along with it.

Black and Indigenous communities are still waiting

The average does not equitably distribute progress

The CDC points out that overdose death rates have long been particularly high among American Indians and Alaska Natives, while many Black communities have experienced trends worse than the average. NPR notes that deaths remain high in many predominantly Black and American Indian communities despite the overall decline.

This isn’t just a matter of statistics. Resources may exist but aren’t distributed equally. Treatment centers may be open but aren’t accessible. Coverage may be theoretically available but remains difficult to access. Trust in a healthcare system is also built on history—and that history hasn’t been kind everywhere.

Equality is measured down to the last community

A dignified national policy does not merely ask whether the overall number is decreasing. It asks where it is decreasing, among whom, with what resources, and for how long. It seeks out the groups that are not benefiting from the progress. Otherwise, general progress becomes a band-aid placed over fractures that continue to widen.

A life saved in Manhattan and a life lost in a rural community do not cancel each other out in a statistic. They demand two distinct responses and the same moral weight.

The average is useful for governing. It becomes dangerous when it teaches us to turn a blind eye.

The death toll does not account for the survivors

Every non-fatal overdose remains uncounted

The data in question measures deaths. It does not account for all averted overdoses, injuries, emergency room visits, relapses, mobilized families, or people living with untreated addiction. A decline in mortality can coexist with immense suffering. It may even reflect a greater ability to prevent death without yet sufficiently reducing the number of overdoses.

The CDC has other systems for tracking emergency room visits and non-fatal overdoses. Their existence serves as a reminder of the obvious: death is the most serious outcome, but not the only one. A policy that ends when the death certificate is not signed reaches its conclusion too soon.

Survival creates a debt of care

Naloxone can bring a person back to life for a day. That day must then offer a real option: treatment, support, housing, transportation, follow-up care, and harm reduction. Without a bridge, the rescue becomes a series of emergencies. With a bridge, it can become the first chapter of something else—without guarantees and without romanticism.

The decline in deaths tells us that more people are staying alive. It does not tell us whether we have built a life around them that is accessible enough for survival to cease being a solitary cycle.

Preventing death is the beginning of responsibility, never its end.

The Political Temptation to Claim Victory

A collective achievement always seeks an owner

When a national indicator improves, each side wants to date the progress to the day after its own decision. But the decline that began in 2023 spans administrations, state budgets, local programs, and cycles of illicit supply. Medications, distribution networks, and healthcare practices take years to take effect. A single signature cannot bring about such a sweeping reversal.

Good policy involves protecting what works even when others take the credit. Bad policy involves celebrating the outcome while cutting the very tools that may have contributed to it. Medical Daily specifically highlights the risks associated with reductions in Medicaid coverage and funding for prevention. These future causal links are not yet measurable. The risk, however, is clear: removing access cannot expand it.

A triumph can become a budget cut

Declaring the crisis resolved makes every program more vulnerable. Naloxone seems less urgent. Community teams seem less necessary. The data give the impression that the downward trend will continue on its own. Yet no trend has a will of its own. It depends on the actions, resources, budgets, and access that shape it.

The greatest danger of good news is that a government will use it as proof that efforts can cease. Progress then becomes the alibi for its own destruction.

A victory declared too soon sometimes begins by disarming those who made it possible.

Medicaid is waiting at the door

Coverage determines whether treatment is available

For many low-income individuals, Medicaid funds a vital portion of treatments for substance use disorders. An approved medication saves no one if the appointment, the prescribing physician, the pharmacy, or transportation remain out of reach. Coverage transforms a medical protocol into a daily reality.

Medical Daily reports on analysts’ concerns regarding potential cuts to coverage and prevention budgets. We must remain cautious: these pages do not demonstrate how many future deaths would be attributable to each decision. They illustrate the mechanism. Less coverage can mean less continuity, more interruptions, and more people pushed into the unregulated market without protection.

The savings come at a cost elsewhere

A budget cut appears immediately in a spreadsheet. Its consequences then ripple through emergency rooms, ambulances, prisons, families, and morgues. Public accounting becomes dishonest when it celebrates savings in one column while ignoring the costs shifted to all the others.

You can reduce treatment costs on paper. You don’t eliminate the disorder, the fentanyl, or the need; you simply push them toward the most expensive and cruel places.

Removing coverage doesn’t make the illness go away. It only removes the bridge.

The CDC’s approach compels us to be humble

Predicting Because Reports Are Late

The National Vital Statistics System receives certificates from the states and publishes rolling 12-month periods. The reported numbers are incomplete, particularly when toxicology investigations remain open. The CDC therefore applies factors based on historical delays to produce provisional projected numbers. Since April 2026, adjustments have been based on the final data from 2024.

This method is necessary. It also has limitations. Exceptional delays in certain states may not be fully corrected. Data completeness varies. The specific drug is not always identified. Categories may overlap when a death involves multiple substances. Comparing jurisdictions too hastily or adding categories together as if they were mutually exclusive leads to a false sense of precision.

Uncertainty is a form of respect

The CDC states that a true decline can only be definitively established with final data. This does not mean we must wait to take action. We often govern based on preliminary indicators. But we must disclose their status and accept that an update may change the figures. Methodological honesty is not a weakness in the eyes of the reader. It is the foundation of their trust.

We do not honor the dead by feigning a certainty that the data itself does not yet possess. We owe them better: a clearly stated trend, its limitations acknowledged, and action taken despite the incompleteness.

Humility does not weaken the numbers. It prevents them from being used against the truth.

What works must remain available

Don’t choose between saving and treating

Risk reduction and treatment are too often pitted against one another. One is said to save without curing; the other to cure without tolerating. This opposition is fruitless. Naloxone keeps a person alive. Methadone or buprenorphine can reduce the risk of relapse. Community support helps people stay on track. No tool deserves to be undermined simply because it doesn’t do the work of all the others.

We must also maintain surveillance. A national decline could mask a local surge or a new combination of substances. Monthly data, emergency room visits, and field reports give communities time to adjust distribution, messaging, and care. Spotting the problem early doesn’t guarantee a rescue. Spotting it too late guarantees we’ll be playing catch-up.

Dignity is not a reward

A person struggling with addiction does not have to pass a moral test to receive an antidote or treatment. Public health does not distribute human worth based on behavioral perfection. It reduces risk, provides care when possible, and starts over when necessary. It’s less dramatic than a condemnation. It’s more in line with life.

The decline in deaths does not give us the right to close our doors. It shows us what happens when more people have an antidote, more patients find treatment, and more teams refuse to give up.

What saves a life should never have to apologize for not saving the whole world.

The next poison won’t send a warning

A Chemical Crisis That Teaches

Fentanyl has transformed the epidemic because it is potent, compact, and easily mixed. Stimulants and sedatives are now adding further layers of complexity. The black market adapts to regulations, shortages, and profits. It doesn’t wait for an agency to update its database. A substance can circulate for a long time before deaths, tests, and reports clearly trace its path.

The response must therefore be able to adapt: rapid testing, local alerts, access to naloxone, opioid treatment, research on stimulants, and support for people who use multiple substances. There is no final wave after which the ocean will settle. There are systems that learn or that repeat.

The border will not replace the hospital

Intercepting precursors and prosecuting traffickers can reduce supply. It does not treat people who are already addicted, does not make an antidote available, and does not shorten the two-hour drive to a clinic. Law enforcement and public health can work together. Pitting them against each other condemns the country to winning a seizure and losing a person.

The next drug blend won’t have the decency to wait for our ideological debate. It will seep into places where care is scarce, where surveillance is slow, and where loneliness is already part of the risk.

A changing crisis demands more than a slogan that stands still.

What the downturn demands of us now

Celebrate Through Continuity

The right way to honor progress is not to downplay the remaining numbers. Nor is it to deny all joy. It is to strengthen the mechanisms that may have contributed: access to naloxone, evidence-based treatments, coverage, surveillance, local teams, and responses tailored to each community. Then to honestly examine the role of supply and changes in consumption.

We must also look at the places where the curve is rising. New Mexico, Arizona, and Colorado are not footnotes. Indigenous, Black, rural, and aging communities are not an acceptable lag in a national victory. The country isn’t done until progress depends less on zip codes.

The number returns with missing faces

67,798. At the start, it was a decline. By the end, it’s a responsibility. Each number represents a person who died during a time when the country was actually doing better. Here’s the hard truth: improvement and the unbearable can coexist on the same line. We must be mature enough to hold onto both.

As long as sixty-seven thousand lives are lost, respite is not an end in itself: it is time borrowed to save even more.

Let’s take a breath. Then let’s keep the door open, because someone is still coming, and they are alive.

Signed, Maxime Marquette, columnist

Columnist’s Transparency Box

Editorial Stance

I am not a journalist, but a columnist and analyst. My expertise lies in observing and analyzing the geopolitical, economic, and strategic dynamics that shape our world. My work consists of dissecting political strategies, understanding global economic trends, contextualizing the decisions of international actors, and offering analytical perspectives on the transformations that are redefining our societies.

I do not claim to possess the dispassionate objectivity of traditional journalism, which is limited to factual reporting. I strive for analytical clarity, rigorous interpretation, and a deep understanding of the complex issues that affect us all. My role is to make sense of the facts, place them within their historical and strategic context, and offer a critical interpretation of events.

Methodology and Sources

This text respects the fundamental distinction between verified facts and interpretive analyses. The methodological rule is consistent: factual information is published only if it is supported by a verifiable source, and the sources actually used in this article are listed under “Sources,” never here.

Categories of primary sources used by the publication, when applicable: official press releases from governments and international institutions, public statements by political leaders, reports from intergovernmental organizations, and dispatches from recognized international news agencies.

Types of secondary sources: specialized publications, internationally recognized news media, analyses from established research institutions, and reports from sector-specific organizations.

When an article cites statistical, economic, or geopolitical data, it comes from data-producing institutions (intergovernmental organizations, central banks, national statistical institutes), and the specific institution is listed under “Sources.”

Nature of the Analysis

The analyses, interpretations, and perspectives presented in the analytical sections of this article constitute a critical and contextual synthesis based on available information, observed trends, and expert commentary cited in the sources consulted.

My role is to interpret these facts, contextualize them within the framework of contemporary geopolitical and economic dynamics, and give them coherent meaning within the broader narrative of the transformations shaping our era. These analyses reflect expertise developed through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a state of affairs documented as of its publication date, not a prediction: subsequent developments may alter these perspectives. No updates are promised in advance; when an article is corrected or supplemented, the change is dated within the text.

COLUMN: 67,798 dead, and America finally dares to breathe, but cannot celebrate